Short answer

Teva Pharmaceutical Industries Ltd (TEVA) filed its Q3 2019 10-Q quarterly report on Nov 7, 2019 for the quarter ended Sep 30, 2019.

Teva Pharmaceutical Industries Ltd Q3 2019 10-Q analysis

AI summary of MD&A and risk factor updates

Revenue $4,264M, down 6% YoY, pressured by COPAXONE competition and lower BENDEKA/TREANDA sales
Gross margin 42.9% vs 43.7% YoY; operating loss $81M vs $16M operating income
Europe strongest: revenue $1,163M, profit $341M, up 15%; North America weakest: revenue $2,051M, profit $565M, down 13%
Operating cash flow $325M vs $421M YoY; cash and investments $1,301M after $1,556M debt repayment
Headwinds: opioid legal provision $468M, FDA remediation risks, continued COPAXONE competition; 2019 non-GAAP tax-rate outlook 18%

Newly added opioid-abuse risk, triggered by escalating U.S. investigations, litigation and regulatory actions
Opioid settlement framework, potential buprenorphine-naloxone supply valued up to approximately $23 billion over 10 years
Opioid settlement framework, potential cash payments up to $250 million over 10 years
Legal proceedings, adverse resolutions could materially harm reputation, operations and cash flows

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.